Amgen Inc. Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value
Amgen Inc. (AMGN) had Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value of $0 as of 2020-12-31, per its 10-K filed 2021-02-09.
Discontinued › Notes › Investments › Debt and Equity Securities › Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue · last filed 2021-02-09
- 2020-12-31: Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value $0.00.
- 2020-09-30: Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value $0.00.
- 2020-06-30: Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value $0.00.
- 2020-03-31: Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value $0.00.
| Period end | Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-09 |
| 2020-09-30 | $0.00 10-Q · filed 2020-10-29 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-29 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-01 |
| 2019-12-31 | $182.00M 10-K · filed 2021-02-09 |
| 2019-09-30 | $559.00M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $1.80B 10-Q · filed 2019-07-31 |
| 2019-03-31 | $1.85B 10-Q · filed 2019-05-01 |
| 2018-12-31 | $1.89B 10-K · filed 2020-02-12 |
| 2018-09-30 | $1.94B 10-Q · filed 2018-10-31 |
| 2018-06-30 | $2.23B 10-Q · filed 2018-07-27 |
| 2017-12-31 | $4.46B 10-K · filed 2019-02-13 |
| 2016-06-30 | $3.92B 10-Q · filed 2016-07-29 |
| 2016-03-31 | $4.06B 10-Q · filed 2016-05-02 |
| 2015-12-31 | $3.94B 10-Q · filed 2016-07-29 |
| 2015-09-30 | $3.73B 10-Q · filed 2015-11-02 |
| 2015-06-30 | $3.51B 10-Q · filed 2015-08-05 |
| 2015-03-31 | $3.28B 10-Q · filed 2015-04-27 |
| 2014-12-31 | $3.50B 10-K · filed 2016-02-16 |
| 2014-09-30 | $3.87B 10-Q · filed 2014-10-29 |
| 2014-06-30 | $3.61B 10-Q · filed 2014-08-05 |
| 2014-03-31 | $2.91B 10-Q · filed 2014-04-30 |
| 2013-12-31 | $2.97B 10-K · filed 2015-02-19 |
| 2013-09-30 | $2.85B 10-Q · filed 2013-10-29 |
| 2013-06-30 | $2.87B 10-Q · filed 2013-08-06 |
| 2013-03-31 | $3.31B 10-Q · filed 2013-05-03 |
| 2012-12-31 | $3.60B 10-K · filed 2014-02-24 |
| 2012-09-30 | $3.90B 10-Q · filed 2012-11-06 |
| 2011-12-31 | $1.78B 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |